Shine-On BioMedical Co.,Ltd. (TPEX:6926)
Taiwan · Delayed Price · Currency is TWD 63.40
-0.10 (-0.16%)
Aug 19, 2026, 9:58 AM CST
Shine-On BioMedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 50.62 | 30 | - | 9.52 | - | - | |
Revenue Growth | - | - | - | - | - | - |
Cost of Revenue | - | - | - | 2.86 | - | - |
Gross Profit | 50.62 | 30 | - | 6.67 | - | - |
Selling, General & Admin | 17.72 | 17.66 | 16.79 | 15.11 | 11.72 | 3.5 |
Research & Development | 228.83 | 137.84 | 119.28 | 54.24 | 6.9 | 7.99 |
Operating Expenses | 246.55 | 155.5 | 136.07 | 69.35 | 18.61 | 11.5 |
Operating Income | -195.93 | -125.5 | -136.07 | -62.68 | -18.61 | -11.5 |
Interest Expense | -0.02 | -0.03 | -0.03 | -0.01 | -0.03 | -0.02 |
Interest & Investment Income | 14.24 | 15.42 | 16.24 | 20.07 | 8.19 | 0.28 |
Currency Exchange Gain (Loss) | - | - | 1.51 | 7.69 | -11.37 | - |
Other Non Operating Income (Expenses) | 0.02 | -0.32 | 0.07 | 0.01 | - | - |
EBT Excluding Unusual Items | -181.69 | -110.42 | -118.29 | -34.94 | -21.82 | -11.24 |
Gain (Loss) on Sale of Investments | - | - | 0.11 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | -0.41 | - | - | - |
Pretax Income | -181.69 | -110.42 | -118.59 | -34.94 | -21.82 | -11.24 |
Income Tax Expense | 0.02 | -0.13 | 0.3 | 2.23 | -2.27 | - |
Net Income | -181.72 | -110.29 | -118.89 | -37.17 | -19.54 | -11.24 |
Net Income to Common | -181.72 | -110.29 | -118.89 | -37.17 | -19.54 | -11.24 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 50 | 50 | 50 | 50 | 45 | 18 |
Shares Outstanding (Diluted) | 50 | 50 | 50 | 50 | 45 | 18 |
Shares Change | 0.63% | 0.21% | - | 9.67% | 145.83% | - |
EPS (Basic) | -3.63 | -2.21 | -2.39 | -0.75 | -0.43 | -0.61 |
EPS (Diluted) | -3.63 | -2.21 | -2.39 | -0.75 | -0.43 | -0.61 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -143.42 | -114.78 | -91.56 | -26.95 | -22.14 | -10.71 |
Free Cash Flow Per Share | -2.87 | -2.30 | -1.84 | -0.54 | -0.49 | -0.58 |
Gross Margin | 100.00% | 100.00% | - | 70.00% | - | - |
Operating Margin | -387.09% | -418.33% | - | -658.16% | - | - |
Profit Margin | -359.00% | -367.62% | - | -390.23% | - | - |
Free Cash Flow Margin | -283.34% | -382.59% | - | -282.94% | - | - |
EBITDA | -193.8 | -123.43 | -135.52 | -61.97 | -18.07 | -11.22 |
D&A For EBITDA | 2.14 | 2.07 | 0.56 | 0.71 | 0.55 | 0.28 |
EBIT | -195.93 | -125.5 | -136.07 | -62.68 | -18.61 | -11.5 |